Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.33 |
| ▸ | NFATC1 | O95644 | 5/20 | 0.33 |
| ▸ | GSK3B | P49841 | 5/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3219728 | 0.88 | HTR6 (0.33) | SCN9ADYRK1ANFATC1GSK3BLOXL2 | |
| SCHEMBL3219635 | 0.79 | KDM5A (0.42) | SCN9ADYRK1ANFATC1GSK3BKCNH2 | |
| SCHEMBL3226537 | 0.79 | SCN9A (0.40) | SCN9ADYRK1ANFATC1GSK3BKCNH2 | |
| SCHEMBL3216499 | 0.78 | SCN9A (0.39) | SCN9ADYRK1ANFATC1GSK3BKCNH2 | |
| Trifluoroacetic Acid SCHEMBL3232865 | 0.77 | KDM5A (0.40) | SCN9AROCK2 | |
| SCHEMBL3210099 | 0.76 | KIF11 (0.37) | SCN9ADYRK1ANFATC1GSK3BKIF11 | |
| SCHEMBL3216733 | 0.71 | DYRK1A (0.43) | DYRK1ANFATC1GSK3BKCNH2 | |
| SCHEMBL3219724 | 0.70 | ELANE (0.37) | SCN9APTGER1 | |
| SCHEMBL3231708 | 0.69 | DYRK1A (0.36) | DYRK1ANFATC1GSK3BKCNH2CHUK | |
| SCHEMBL3223476 | 0.69 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | claimed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | claimed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | claimed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | claimed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | claimed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | SCN9A 3307/4885DYRK1A 3842/4885NFATC1 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.